Liftstream is an executive search recruitment company in the life sciences sector
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Posted in Orphan Drugs and Rare Diseases
Tagged AbbVie, Actelion, Alexion, bioValley, Boston, Boston Biotech, Flemming Ornskov, M&A, NPS Pharmaceuticals, Orphan Drug, Pfizer, Rare Disease, Shire, SOBI, Swiss, Synageva
Leave a comment
PAH franchise and cost cutting prevent Actelion from listing further
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Actelion, cost cutting, dual endothelin receptor antagonist, Elliott Advisors, FDA, GSK, Jean-Paul Clozel, JP Garnier, Opsumit, Orphan drugs, PAH, pulmonary arterial hypertension, rare diseases, Switzerland, Tracleer
Leave a comment
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events:
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Actelion, Alexion, BioMarin, BlubirdBio, Chiesi, Elelyso, Emil Kakkis, Enobia, Forbes, Genzyme, IPO, Lysogene, M&A, Prosensa, Protalix, rare diseases, regulatory affairs, regulatory approval, Replagal, Sanofi, Shire, Soliris, Supernus Pharmaceuticals, ultra-rare diseases, Ultragenyx, uniQure, VPRIV
Leave a comment